Citigroup Cuts Owens & Minor (NYSE:OMI) Price Target to $18.50

Owens & Minor (NYSE:OMI) had its price objective cut by Citigroup from $21.00 to $18.50 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also commented on the company. Barclays decreased their target price on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. decreased their price objective on Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a report on Wednesday, August 21st. Robert W. Baird cut their target price on Owens & Minor from $19.00 to $14.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a research note on Monday, August 26th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $18.50.

Owens & Minor Trading Down 1.8 %

Shares of NYSE:OMI traded down $0.23 during mid-day trading on Tuesday, reaching $12.53. 25,801 shares of the company’s stock were exchanged, compared to its average volume of 834,575. The firm has a market capitalization of $966.01 million, a price-to-earnings ratio of -19.63, a PEG ratio of 0.39 and a beta of 0.41. Owens & Minor has a twelve month low of $11.42 and a twelve month high of $28.35. The business’s fifty day moving average price is $14.35 and its 200-day moving average price is $16.06. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.51 and a current ratio of 1.09.

Owens & Minor (NYSE:OMI) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.68 billion. During the same period in the prior year, the firm posted $0.44 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, research analysts predict that Owens & Minor will post 1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Owens & Minor

Large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its holdings in shares of Owens & Minor by 43,142.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,027 shares of the company’s stock valued at $84,000 after purchasing an additional 3,020 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Owens & Minor by 118.2% in the 1st quarter. BNP Paribas Financial Markets now owns 47,587 shares of the company’s stock valued at $1,319,000 after buying an additional 25,779 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Owens & Minor in the 1st quarter valued at about $358,000. Texas Permanent School Fund Corp lifted its position in shares of Owens & Minor by 1.8% during the 1st quarter. Texas Permanent School Fund Corp now owns 66,953 shares of the company’s stock worth $1,855,000 after buying an additional 1,156 shares in the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Owens & Minor by 8.2% in the 1st quarter. Empowered Funds LLC now owns 297,574 shares of the company’s stock worth $8,246,000 after buying an additional 22,509 shares during the last quarter. 98.04% of the stock is currently owned by institutional investors.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.